PharmacoEconomics & Outcomes News 580 - 13 Jun 2009 Bevacizumab adds value in triple- negative breast cancer According to results of a study presented at the 14th Annual International Meeting of the ISPOR, recently held in Orlando, Florida, US, adding bevacizumab to an adjuvant chemotherapy regimen for patients with early triple-negative breast cancer (TNBC) provides short- term reductions in the risk of disease recurrence, projected to improve quality-adjusted survival and potentially be cost effective. Researchers used a Markov model to determine the impact of adding one year of adjuvant treatment with bevacizumab to an established chemotherapy regimen. The probability of disease recurrence was derived from a prospective clinical database of 255 patients with early TNBC. Total direct medical costs and quality-adjusted life-years (QALYs) were projected over a lifetime from the perspective of the UK NHS. Mean discounted quality-adjusted life expectancy was expected to increase by 0.83 QALYs after the addition of bevacizumab to chemotherapy versus chemotherapy alone (11.35 vs 10.53 QALYs). Over patient lifetimes, bevacizumab was associated with higher discounted total direct costs, primarily due to higher pharmacy costs and the increased time spent in disease-free survival. These results were associated with an incremental cost-effectiveness ratio of ≤ £43 804/QALY gained. Ray JA, et al. Projected long-term economic outcomes associated with bevacizumab treatment in patients with adjuvant triple-negative breast cancer to inform early decision making. 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : 45-46 abstr. PCN51, 16 May 2009. 801143429 1 PharmacoEconomics & Outcomes News 13 Jun 2009 No. 580 1173-5503/10/0580-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Bevacizumab adds value in triple-negative breast cancer

Download PDF Report

Upload
vutuong
View
214
Download
2

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 580 - 13 Jun 2009

Bevacizumab adds value in triple-negative breast cancer

According to results of a study presented at the 14thAnnual International Meeting of the ISPOR, recentlyheld in Orlando, Florida, US, adding bevacizumab to anadjuvant chemotherapy regimen for patients with earlytriple-negative breast cancer (TNBC) provides short-term reductions in the risk of disease recurrence,projected to improve quality-adjusted survival andpotentially be cost effective.

Researchers used a Markov model to determine theimpact of adding one year of adjuvant treatment withbevacizumab to an established chemotherapy regimen.The probability of disease recurrence was derived from aprospective clinical database of 255 patients with earlyTNBC. Total direct medical costs and quality-adjustedlife-years (QALYs) were projected over a lifetime fromthe perspective of the UK NHS.

Mean discounted quality-adjusted life expectancy wasexpected to increase by 0.83 QALYs after the addition ofbevacizumab to chemotherapy versus chemotherapyalone (11.35 vs 10.53 QALYs). Over patient lifetimes,bevacizumab was associated with higher discountedtotal direct costs, primarily due to higher pharmacycosts and the increased time spent in disease-freesurvival. These results were associated with anincremental cost-effectiveness ratio of ≤ £43 804/QALYgained.Ray JA, et al. Projected long-term economic outcomes associated withbevacizumab treatment in patients with adjuvant triple-negative breast cancer toinform early decision making. 14th Annual International Meeting of theInternational Society for Pharmacoeconomics and Outcomes Research : 45-46abstr. PCN51, 16 May 2009. 801143429

$Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan versus Cetuximab/Bevacizumab in Irinotecan-Refractory Colorectal Cancer LB Saltz, HJ Lenz,$